Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Molecular Diagnostics › PARP Inhibitor Response Markers Still Key Consideration in Ovarian Cancer Despite Broad Indications

PARP Inhibitor Response Markers Still Key Consideration in Ovarian Cancer Despite Broad Indications

Jun 04, 2020
|
Andrea Anderson
Premium

NEW YORK – At the recent American Society of Clinical Oncology's virtual annual meeting, Andrés Poveda shared results from the Phase III SOLO-2 clinical trial of olaparib (AstraZeneca/Merck's Lynparza) maintenance therapy for women with chemotherapy-sensitive, relapsed ovarian cancer and pathogenic BRCA1/2 mutations — a patient group that had an average survival benefit of more than a year on the PARP inhibitor.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jul
16
Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Cancer

  1. Genetic Testing Challenges in Oncology: Lynch Syndrome Patient Has Ovaries, Uterus Removed at Age 22

  2. AnchorDx Demonstrates Liquid Biopsy DNA Methylation Test for Early Cancer Detection

    Premium

  3. Pfizer's Ibrance Shows 'Modest' Antitumor Activity in Patients With CDKN2A-Altered Lung Cancer

  4. Polygenic Risk Score Modifies Breast Cancer Risk in Pathogenic Variant Carriers

  5. Daiichi Sankyo Adds TNBC Cohort to TROP2-Directed Antibody Study

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.